Gene therapy using recombinant adenoviral vectors represents a promising therapeutic tool to prevent vein graft stenosis, the main complication of coronary artery bypass grafting. However, the low transduction efficiency of vascular smooth muscle cells and endothelial cells (EC) is a potential limitation, presumably due to the low levels of functional adenovirus receptor (coxsackie:adenovirus receptor; CAR). Designing vectors specifically targeted to αv integrins is a strategy that might overcome the poor expression of CAR in vascular smooth muscle cells and EC. RGD, a receptor-binding motif that can interact with αv integrins, was inserted into the HI loop and at the C-terminus of the adenoviral fiber protein in two separate adenovirus vectors encoding a β-galactosidase reporter gene. Av1nBgCRGD (C-terminus) and Av1nBgHIRGD (HI loop) were evaluated in EC in culture and in jugular vein organ culture. Transduction of primary rat and rabbit EC with Av1nBgHIRGD was significantly more efficient when compared to Av1nBgCRGD or Av1nBg. Transduction of mouse, rat and rabbit jugular veins in organ culture using Av1nBg showed that adenovirus-mediated gene expression was greatest in rabbit jugular veins compared to rat and mouse veins. Av1nBgHIRGD augmented gene expression approximately four-fold in rabbit jugular veins when compared to Av1nBg. Histochemical analysis showed that numerous EC but few smooth muscle cells were transduced at all vector concentrations. A substantial number of adventitial fibroblasts were transduced only at the highest vector concentrations of Av1nBgHIRGD. These findings demonstrate that integrin-targeted vectors allow for enhanced gene delivery to veins and strengthen the viability of adenoviral-mediated gene transfer of therapeutic transgenes to human veins prior to vein grafting.

Keywords:
Adenovirus, Targeted adenoviral vectors, Jugular veins, Gene therapy
1.
Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, Golding LA, Gill CC, Taylor PC, Sheldon WC, et al: Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986;314:1–6.
2.
Cameron A, Davis KB, Green G, Schaff HV: Coronary bypass surgery with internal-thoracic-artery grafts – effects on survival over a 15-year period. N Engl J Med 1996;334:216–219.
3.
Yang ZH, Stulz P, von Segesser L, Bauer E, Turina M, Luscher TF: Different interactions of platelets with arterial and venous coronary bypass vessels. Lancet 1991;337:939–943.
4.
Angelini GD, Newby AC: The future of saphenous vein as a coronary artery bypass conduit. Eur Heart J 1989;10:273–280.
5.
Kalan JM, Roberts WC: Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1 year: Necropsy analysis of 53 patients, 123 saphenous veins, and 1,865 five-millimeter segments of veins. Am Heart J 1990;119:1164–1184.
6.
Cable DG, Caccitolo JA, Caplice N, O’Brien T, Simari RD, Daly RC, Dearani JA, Mullany CJ, Orszulak TA, Schaff HV: The role of gene therapy for intimal hyperplasia of bypass grafts. Circulation 1999;100(suppl 19):II392–II396.
7.
Newby AC, Baker AH: Targets for gene therapy of vein grafts. Curr Opin Cardiol 1999;14:489–494.
8.
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993;73:309–319.
9.
Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320–1323.
10.
Stevenson SC, Rollence M, White B, Weaver L, McClelland A: Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol 1995;69:2850–2857.
11.
Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA: Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J 1997;16:2294–2306.
12.
Bai M, Harfe B, Freimuth P: Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J Virol 1993;67:5198–5205.
13.
Nemerow GR, Stewart PL: Role of alpha(v) integrins in adenovirus cell entry and gene delivery. Microbiol Mol Biol Rev 1999;63:725–734.
14.
Stevenson SC, Rollence M, Marshall-Neff J, McClelland A: Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol 1997;71:4782–4790.
15.
Pasqualini R, Koivunen E, Ruoslahti E: Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997;15:542–546.
16.
Horton RM, Cai ZL, Ho SN, Pease LR: Gene splicing by overlap extension: Tailor-made genes using the polymerase chain reaction. Biotechniques 1990;8:528–535.
17.
Gorziglia MI, Kadan MJ, Yei S, Lim J, Lee GM, Luthra R, Trapnell BC: Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 1996;70:4173–4178.
18.
Xia D, Henry LJ, Gerard RD, Deisenhofer J: Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure 1994;2:1259–1270.
19.
Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M: Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996;70:4805–4810.
20.
Mittereder N, Yei S, Bachurski C, Cuppoletti J, Whitsett JA, Tolstoshev P, Trapnell BC: Evaluation of the efficacy and safety of in vitro, adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther 1994;5:717–729.
21.
George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH: Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 1998;9:867–877.
22.
Baker AH, Mehta D, George SJ, Angelini GD: Prevention of vein graft failure: Potential applications for gene therapy. Cardiovasc Res 1997;35:442–450.
23.
Worgall S, Leopold PL, Wolff G, Ferris B, Van Roijen N, Crystal RG: Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum Gene Ther 1997;8:1675–1684.
24.
Yang Y, Wilson JM: Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 1995;155:2564–2570.
25.
Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell’Acqua G, Dzau VJ: Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet 1999;354:1493–1498.
26.
Channon KM, Fulton GJ, Gray JL, Annex BH, Shetty GA, Blazing MA, Peters KG, Hagen PO, George SE: Efficient adenoviral gene transfer to early venous bypass grafts: Comparison with native vessels. Cardiovasc Res 1997;35:505–513.
27.
Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM, Kovesdi I: Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996;70:6831–6838.
28.
Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT: Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996;14:1574–1578.
29.
Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP, Baird A, Campain JA, Curiel DT: Targeted gene delivery to Kaposi’s sarcoma cells via the fibroblast growth factor receptor. Cancer Res 1997;57:1447–1451.
30.
Rancourt C, Rogers BE, Sosnowski BA, Wang M, Piche A, Pierce GF, Alvarez RD, Siegal GP, Douglas JT, Curiel DT: Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998;4:2455–2461.
31.
Wickham TJ, Tzeng E, Shears LL, Roelvink PW, Li Y, Lee GM, Brough DE, Lizonova A, Kovesdi I: Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997;71:8221–8229.
32.
McDonald GA, Zhu G, Li Y, Kovesdi I, Wickham TJ, Sukhatme VP: Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vector. J Gene Med 1999;1:103–110.
33.
Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT: An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706–9713.
34.
Kasono K, Blackwell JL, Douglas JT, Dmitriev I, Strong TV, Reynolds P, Kropf DA, Carroll WR, Peters GE, Bucy RP, Curiel DT, Krasnykh V: Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res 1999;5:2571–2579.
35.
Asimakopoulos G, Taylor KM: Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Ann Thorac Surg 1998;66:2135–2144.
36.
Takala AJ, Jousela IT, Takkunen OS, Jansson SE, Kyosola KT, Olkkola KT, Leirisalo-Repo M, Repo H: Time course of beta 2-integrin CD11b/CD18 (Mac-1, alpha M beta 2) upregulation on neutrophils and monocytes after coronary artery bypass grafting. CD11b upregulation after CABG surgery. Scand J Thorac Cardiovasc Surg 1996;30:141–148.
37.
Rainger GE, Buckley CD, Simmons DL, Nash GB: Neutrophils sense flow-generated stress and direct their migration through alphaVbeta3-integrin. Am J Physiol 1999;276:H858–H864.
38.
Meng X, Mavromatis K, Galis ZS: Mechanical stretching of human saphenous vein grafts induces expression and activation of matrix-degrading enzymes associated with vascular tissue injury and repair. Exp Mol Pathol 1999;66:227–237.
39.
Racanelli AL, Gibbs SK, Schlingmann KL, Corjay MH, Jadhav PK, Reilly TM: Inhibition of neointima formation by a nonpeptide alpha(v)beta(3) integrin receptor antagonist in a rabbit cuff model. J Cell Biochem 2000;77:213–220.
40.
Wickham TJ, Haskard D, Segal D, Kovesdi I: Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation. Cancer Immunol Immunother 1997;45:149–151.
41.
Kibbe MR, Nie S, Yoneyama T, Hatakeyama K, Lizonova A, Kovesdi I, Billiar TR, Tzeng E: Optimization of ex vivo inducible nitric oxide synthase gene transfer to vein grafts. Surgery 1999;126:323–329.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.